26872 Federal Register / Vol. 66, No. 94 / Tuesday, May 15, 2001 / Notices

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Discovery of Proteins That Are

Aberrantly Expressed in Laser Capture

Microdissected Human Solid Tumors

Emmanuel Petricoin (FDA), Lance Liotta

(NCI), Michael Emmert-Buck (NCI),

Yingming Zhao (EM)

DHHS Reference No. E–083–01/0 filed

01 February 2001

Licensing Contact: Matthew Kiser; 301/

496–7735 ext. 224; e-mail:

kiserm@od.nih.gov

The post-genomic era has created a

need for a direct method to monitor the

levels of expressed proteins in

developing, diseased or genetically

altered tissues. Direct monitoring of

tissue has proven difficult because of

the heterologous, three-dimensional

structure. Prior methods for extracting

and analyzing biomolecules from tissue

subpopulations were complicated, labor

intensive, and did not utilize protein

stabilizers. There has been no way to

directly compare, without the danger of

cross-contamination, the spectrum of

proteins contained in normal cells with

the proteins in tumor cells in a single

tissue. Many of the hypotheses

regarding altered protein levels in tumor

cells have been based on work on cell

lines and their viability in culture

media. The amount and type of protein

expressed by cells in the native tissue

environment can be quite different than

that of cultured cells. Thus, the need

exists for a direct means of measuring

protein levels to obtain results reflecting

in vivo conditions. This technology

supplies the means to obtain in vivo

expression levels.

The present invention describes

devices and methods for performing

protein analysis on laser capture

microdissected cells, which facilitate

proteomic analysis on cells of different

populations. The protein content can be

determined by any of the standard

analytical techniques: immunoassays,

1D and 2D electrophoresis, Western

blotting, LCQ–MS, MALDI/TOF, and

SELDI. Specific applications include,

but are not limited to, analysis of

normal versus malignant cells,

differential expression determination of

cellular proteins at various disease

states (e.g. normal, pre-malignant,

tumor), and comparison of expression

levels of different types of cancers (e.g.

esophageal, prostate, breast, ovarian,

lung, and colon cancer).

A second embodiment of this

technology provides specific examples

of tumor or tumor-stage linked protein

‘‘fingerprints’’ and specific proteins

identified from these ‘‘fingerprints’’ as

being aberrantly expressed in specific

diseased cell types. Furthermore,

methods of using these ‘‘fingerprints’’,

sub-sets thereof, and individual proteins

in the diagnosis, prognosis, treatment,

treatment selection, and drug

development for disease are provided.

Production and Use of Anti-Dorsalizing

Morphogenetic Protein

M. Moos Jr., M. Krinks, S. Wang (FDA)

Serial No. 08/335,583 filed 08 Nov 1994,

now US Patent 5,693,779 issued 02

Dec 1997

Licensing Contact: Susan S. Rucker;

301/496–7056 ext. 245; e-mail:

ruckers@od.nih.gov

This patent relates to the

identification, isolation and cloning of

the cDNA which encodes a protein,

Anti-Dorsalizing Morphogenetic

Protein-1 (ADMP–1). ADMP–1 is related

to the bone morphogenetic proteins and

is a member of the TGF beta

superfamily. ADMP–1 is involved in the

down-regulation of multiple factors

related to tissue proliferation and may

be useful in inhibiting inappropriate

tissue proliferation such as that

associated with psoriasis or melanoma.

This work has been published, in

part, at Moos, M, et al. ‘‘Anti-dorsalizing

morphogenetic protein is a novel TGFbeta homolog expressed in the Spemann

organizer’’ Development 121(12):4293–

301 (Dec 1995).

Dated: May 7, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 01–12126 Filed 5–14–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Center for Complementary &

Alternative Medicine; Notice of Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the National Advisory

Council for Complementary and

Alternative Medicine (NACCAM).

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications

and/or contract proposals and the

discussions could disclose confidential

trade secrets or commercial property

such as patentable material, and

personal information concerning

individuals associated with the grant

applications and/or contract proposals,

the disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Advisory

Council for Complementary and Alternative

Medicine.

Date: May 31, 2001.

Open: 8 a.m. to 2:45 p.m.

Agenda: The agenda includes the Opening

Remarks by Director, NCCAM, reports on

NCCAM Intramural Program, NCCAM Health

Disparities Plan, IRB Discussion, CAPCAM/

Best Case Series Update, Public Comments,

and other business of the Council.

Closed: 2:45 p.m. to adjournment.

Agenda: To review and evaluate grant

applications and/or proposals.

Place: Natcher Conference Center, 45

Center Drive, Bethesda, MD 20892.

Contact Person: Richard Nahin, Ph.D.,

Executive Secretary, National Center for

Complementary and Alternative Medicine,

National Institutes of Health, 6707

Democracy Blvd, Suite 106, Bethesda, MD

20892, 301/496–7801.

The public comments session is

scheduled on from 11:15–11:45 a.m.

Each speaker will be permitted 5

minutes for their presentation.

Interested individuals and

representatives of organizations are

requested to notify Dr. Richard Nahin,

National Center for Complementary and

Alternative Medicine, HIH, 6707

Democracy Boulevard, Suite 106,

Bethesda, Maryland, 20892, 301–496–

Federal Register / Vol. 66, No. 94 / Tuesday, May 15, 2001 / Notices 26873

7801, Fax: 301–480–3621. Letters of

intent to present comments, along with

a brief description of the organization

represented, should be received no later

than 5 p.m. on May 25, 2001. Only one

representative of an organization may

present oral comments. Any person

attending the meeting who does not

request an opportunity to speak in

advance of the meeting may be

considered for oral presentation, if time

permits, and at the discretion of the

Chairperson. In addition, written

comments may be submitted to Dr.

Nahin at the address listed above up to

ten calendar days (June 10, 2001)

following the meeting.

Copies of the meeting agenda and the

roster of members will be furnished

upon request by Dr. Richard Nahin,

Executive Secretary, NACCAM,

National Institutes of Health, 6707

Democracy Boulevard, Suite 106,

Bethesda, Maryland 20892, (301) 496–

7801, Fax 301–480–3621.

Dated: May 4. 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy, NIH.

[FR Doc. 01–12119 Filed 5–14–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Environmental

Health Sciences; Notice of Closed

Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Environmental Health Sciences Special

Emphasis Panel Review of RFA TW–01–002,

International Training & Research in

Environmental & Occupational Health.

Date: June 13–15, 2001.

Time: 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant

applications.

Place: Hawthorne Suites, 300 Meredith

Drive, Durham, NC 27713.

Contact Person: Brenda K Weis, Ph.D,

Scientific Review Administrator, Scientific

Review Branch, Division of Extramural

Research and Training, National Institutes of

Environmental Health Sciences, P.O. Box

12233, MD/EC–30, Research Triangle Park,

NC 27709, 919/541–4964.

Name of Committee: National Institute of

Environmental Health Sciences Special

Emphasis Panel Review Meeting for RFA

001–002—Toxicogenomics.

Date: June 19–22, 2001.

Time: 7 p.m. to 12 p.m.

Agenda: To review and evaluate grant

applications.

Place: Radisson Governors Inn, I–40 and

Davis Dr., Exit 280, Research Triangle Park,

NC 27709.

Contact Person: Linda K. Bass, Ph.D,

Scientific Review Administrator, National

Institute of Environmental Health Sciences,

P.O. Box 12233, MD EC–30, Research

Triangle Park, NC 27709, (919) 541–1307.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.113, Biological Response to

Environmental Response to Environmental

Health Hazards; 93.114, Applied

Toxicological Research and Testing; 93.115,

Biometry and Risk Estimation—Health Risks

from Environmental Exposures; 93.142,

NIEHS Hazardous Waste Worker Health and

Safety Training; 93.143, NIEHS Superfund

Hazardous Substances—Basic Research and

Education; 93.894, Resources and Manpower

Development in the Environmental Health

Sciences, National Institutes of Health, HHS)

Dated: May 4, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–12118 Filed 5–14–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Arthritis and

Musculoskeletal and Skin Diseases;

Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: Arthritis and

Musculoskeletal and Skin Diseases Special

Grants Review Committee.

Date: June 19, 2001.

Time: 8:30 a.m. to 3 p.m.

Agenda: To review and evaluate grant

applications.

Place: Georgetown Holiday Inn, 2101

Wisconsin Ave, NW., Washington, DC 20007.

Contact Person: John R. Lymangrover, PhD,

Scientific Review Administrator, National

Institutes of Health, NIAMS, Natcher Bldg.,

Room 5As25N, Bethesda, MD 20892, 301–

594–4952.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.846, Arthritis,

Musculoskeletal and Skin Diseases Research,

National Institutes of Health, HHS)

Dated: May 3, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–12121 Filed 5–14–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Neurological

Disorders and Stroke; Notice of Closed

Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: Training Grant and

Career Development Review Committee.

Date: June 7–8, 2001.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant

applications.

Place: Hotel Washington, 515 15th Street

NW, Washington, DC 20004.

Contact Person: Raul A. Saavedra, Ph.D,

Scientific Review Administrator, Scientific

Review Branch, Division of Extramural

Research, NINDS/NIH/DHHS, Neuroscience

Center, 6001 Executive Blvd., Suite 3208,

MSC 9529, Bethesda, MD 20892–9529, 301–

496–9223.

Name of Committee: National Institute of

Neurological Disorders and Stroke Initial

Review Group Neurological Sciences and

Disorders A.